CBT Pharmaceuticals licenses a novel recombinant antibody from Crown Bioscience

| By | Cancer Drugs, Clinical Trials, Drug Development
0
564

Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announced a strategic licensing agreement with CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company committed to becoming a leader in the discovery and development of oncology combination therapies.

The agreement gives CBT exclusive world-wide development and commercialization rights to a novel, recombinant, human monoclonal antibody which targets a differentiated epitope on the cytotoxic T-lymphocyte antigen-4 (CTLA-4) molecule. Binding of this antibody to CTLA-4 blocks the interaction of CTLA-4 with its ligands CD80/CD86 thus allowing the cytotoxic T cells to function actively.

Under the terms of this global licensing agreement, CBT gains access to a third checkpoint inhibitor to complement the existing immuno-oncology pipeline of PD-1 and PD-L1 inhibitors. CrownBio is eligible to receive potential future development, regulatory and sales-based milestones payments over $47 million, as well as royalties on net sales. Once the recommended Phase 1 monotherapy portion of the Phase 1/2 trial is completed, combination with other complementary therapies in CBT’s immuno-oncology and targeted therapy portfolios will be initiated.

SOURCE: crown bioscience
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.